HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy

This article was originally published in The Tan Sheet

Executive Summary

The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling

You may also be interested in...

On Pre-emption, OTC Rule Among Signs Tipping Obama Administration’s Hand

FDA has not altered its support of pre-emption in product liability suits but there are signs it will happen under the Obama administration

High Court’s Wyeth v. Levine Ruling Returns Pre-Emption Status Quo

The Supreme Court's ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from state product liability lawsuits, but is not expected to trigger a sea-change in current industry operations

Supreme Court Ties On FDA Pre-Emption; Congress Seeks To Resolve Issue

Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts